Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.79 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.79 |
| ▸ | RAB9A | P51151 | 1/20 | 0.79 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 7/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.70 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13297977 | 0.86 | SLC12A2 (0.92) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL19264910 | 0.86 | SLC12A2 (0.92) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL1423782 | 0.86 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL4763389 | 0.86 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL4077665 | 0.85 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL10282764 | 0.83 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL28001439 | 0.83 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL12169365 | 0.82 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL14132588 | 0.82 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL1874466 | 0.81 | LMNA (0.72) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| EP-1866306-B1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| EP-1866306-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | Nycomed GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103255-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NOS2, NOS1, ARG1 | ALDH1A1 291/4885SMN1; SMN2 3333/4885NR2F2 1705/4885 |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NOS2, NOS1, ARG1 | ALDH1A1 291/4885SMN1; SMN2 3333/4885NR2F2 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.